Pages that link to "Q28081642"
Jump to navigation
Jump to search
The following pages link to CAR therapy: the CD19 paradigm (Q28081642):
Displaying 50 items.
- Marrow-Infiltrating Lymphocytes - Role in Biology and Cancer Therapy (Q26749560) (← links)
- Recent Developments in Cellular Immunotherapy for HSCT-Associated Complications (Q28079823) (← links)
- Immunotherapy in hematologic malignancies: past, present, and future (Q33593865) (← links)
- Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells (Q33833475) (← links)
- Biology and clinical application of CAR T cells for B cell malignancies (Q33907565) (← links)
- In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. (Q34048101) (← links)
- The quest for spatio-temporal control of CAR T cells (Q35843767) (← links)
- Chimeric antigen receptor-modified T cells strike back (Q37040370) (← links)
- Chemotherapy and immunotherapy: A close interplay to fight cancer? (Q37222184) (← links)
- Immunogenicity of self tumor associated proteins is enhanced through protein truncation (Q37481401) (← links)
- Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing (Q37710498) (← links)
- Cancer immunotherapy: harnessing the immune system to battle cancer (Q38577828) (← links)
- Chimeric antigen receptor T-cell therapies for lymphoma (Q38600697) (← links)
- Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab (Q38639698) (← links)
- Synthetic biology: applying biological circuits beyond novel therapies (Q38679815) (← links)
- The Approach to Acute Lymphoblastic Leukemia in Older Patients: Conventional Treatments and Emerging Therapies (Q38759431) (← links)
- Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies. (Q38768392) (← links)
- Driving gene-engineered T cell immunotherapy of cancer (Q38777742) (← links)
- Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China (Q38786626) (← links)
- Recent advances in T-cell immunotherapy for haematological malignancies (Q38789518) (← links)
- Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors (Q38839878) (← links)
- Chimeric antigen receptors: driving immunology towards synthetic biology (Q38884383) (← links)
- Who Should Receive a Transplant for Acute Lymphoblastic Leukaemia? (Q38953608) (← links)
- Promising Novel Agents for Aggressive B-Cell Lymphoma (Q39020641) (← links)
- Immune targets and neoantigens for cancer immunotherapy and precision medicine (Q39057617) (← links)
- The landscape of new drugs in lymphoma (Q39061630) (← links)
- CAR T-cell therapy for pancreatic cancer. (Q39202440) (← links)
- Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective (Q39272183) (← links)
- CAR T-cell therapy for lung cancer and malignant pleural mesothelioma (Q39305346) (← links)
- Engineering Natural Killer Cells for Cancer Immunotherapy (Q39408704) (← links)
- Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers. (Q40064246) (← links)
- Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy (Q40095482) (← links)
- Therapeutic T cell engineering (Q40199809) (← links)
- Mesothelin-targeting chimeric antigen receptor-modified T cells by piggyBac transposon system suppress the growth of bile duct carcinoma (Q40256333) (← links)
- Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. (Q40323802) (← links)
- Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells (Q40965523) (← links)
- Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. (Q41131801) (← links)
- Combinatorial Antigen Targeting: Ideal T-Cell Sensing and Anti-Tumor Response (Q41365864) (← links)
- Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy (Q41432593) (← links)
- Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy (Q41809391) (← links)
- Amatuximab and novel agents targeting mesothelin for solid tumors (Q47126660) (← links)
- Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. (Q47129409) (← links)
- Posttransplant chimeric antigen receptor therapy (Q47550219) (← links)
- CAR T cell therapy for multiple myeloma: where are we now and where are we headed? (Q47565827) (← links)
- Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML. (Q47583493) (← links)
- Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors (Q47855599) (← links)
- An APRIL based chimeric antigen receptor for dual targeting of BCMA and TACI in Multiple Myeloma. (Q48334966) (← links)
- The impact of antibiotic usage on the efficacy of chemoimmunotherapy is contingent on the source of tumor-reactive T cells (Q49276632) (← links)
- Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients. (Q49363296) (← links)
- Drug development in the era of precision medicine. (Q50020853) (← links)